trending Market Intelligence /marketintelligence/en/news-insights/trending/wmhLM9qjeIyNVM5yfd25Zg2 content esgSubNav
In This List

China FDA accepts FibroGen's application for anemia treatment

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


China FDA accepts FibroGen's application for anemia treatment

The China Food and Drug Administration accepted FibroGen Inc.'s new drug application for roxadustat.

Roxadustat is indicated for treating anemia, a deficiency of red blood cells, in patients with dialysis-dependent chronic kidney disease, or CKD, and non-dialysis-dependent CKD.

The new drug application submission also triggered a $15 million milestone payment from AstraZeneca PLC payable to FibroGen under a deal between the two companies. FibroGen is co-developing roxadustat with AstraZeneca.

The application is based on the results of two phase 3 studies.